Skip to main content
. 2023 Mar 1;72(7):2197–2204. doi: 10.1007/s00262-023-03399-2

Table 2.

Tumour responses based on RECIST 1.1

Evaluable patients (n = 31)
Objective response rate (95% CI) 32.3(14.8 − 49.7)
Complete response (n, %) 0
Partial response (n, %) 10(32.3)
Stable disease (n, %) 17(54.8)
Progressive disease (n, %) 4(12.9)
DCR (n, %), 95% CI 87.1(74.6 − 99.6)
Median overall survival, months (95% CI) 11.7(8.3 − 12.9)
Median progression-free survival, months (95% CI) 7.9(7.1 − 8.7)

DCR, disease control rate; RECIST, response evaluation criteria in solid tumors